Manager II Bioagilytix Durham, North Carolina, United States
RNA-based therapeutics represent a growing therapeutic modality in drug development. These molecules range in complexity in nucleotide backbone chemistries and conjugation with other molecules to enhance targeting and delivery. Bioanalytical methods for assessment of these drugs have evolved with different platforms that trade off in superior sensitivity and specificity including LC-MS/MS, qPCR and hybridization ELISAs. This presentation will focus on a case study that will highlight the bioanalytical consideration for choosing the appropriate format of hybridization ELISA, challenges with optimization of these types of assays and recommendations for developing robust hybridization immunoassays.
Learning Objectives:
Upon completion, participants will be able to understand the challenges and considerations for developing robust and sensitive hybridization ELISA assays.
Participants will learn strengths and weaknessess of Immunoassay selection for quanitification of RNA-based therapeutics.
Discussion of common areas for troubleshooting hybridization Immunoassays.
